海普瑞(09989.HK)2020業績:營收增15.3%至53.16億元,藥物製劑開拓多個重大新市場機遇
格隆匯 3 月 29日丨海普瑞(09989.HK)公佈年度業績,截至2020年12月31日止年度,公司收入為人民幣53.16億元,同比增長15.3%;毛利為人民幣20.17億元,同比增長20.6%;非《國際財務報吿準則》的母公司持有者的應占溢利為人民幣5.92億元,同比增長32.6%;經調整非《國際財務報吿準則》的母公司持有者的應占溢利為人民幣8.53億元,同比增長95.7%,每股基本盈利為人民幣0.76元。
集團主要運營三個主要業務分部,包括製劑業務;肝素API業務;及CDMO業務。報吿期內,依諾肝素鈉製劑銷售額收入約人民幣15.107億元,同比增長約22.7%,佔集團總銷售收入28.4%,較2019年上升1.7個百分點;肝素API業務銷售額約人民幣27.009億元,同比增長約18.8%;CDMO業務的銷售額約人民幣7.974億元,同比增長約1.4%,佔集團總收入15.0%。
此外,集團流動資金狀況仍維持強勁。於2020年12月31日,集團的現金及銀行結餘約人民幣13.302億元(2019年12月31日:約人民幣10.765億元)。
公吿稱,藥物製劑業務銷售按年增長22.7%,量價齊升,藥物製劑於2020年下半年開拓多個重大新市場機遇,包括北美、瑞士、沙特阿拉伯,及率先獲得中國一致性評價,為2021年增長奠定良好基礎。CDMO業務的在手訂單(Backlog)按年增長98%至金額約1億美元。依諾肝素鈉就新型冠狀病毒治療成效的III期臨牀試驗病人入組已完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.